TDC
EVH icon

Thompson Davis & Co’s Evolent Health EVH Stock Holding History

Thompson Davis & Co’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,125
Closed -$364K – 103
2022
Q3 		$364K Buy
+10,125
New +$357K 0.49% 37
2017
Q2 		– Sell
-875
Closed -$20K – 1103
2017
Q1 		$20K Buy
+875
New +$16.8K 0.03% 490

Other funds holding EVH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

Thompson Davis & Co's EVH Position: Q4 2022 in Review

Thompson Davis & Co sold out of Evolent Health (EVH) in Q4 2022, closing a stake of 10,125 shares — an estimated $364K sold.

Thompson Davis & Co first reported a position in EVH in Q1 2017 and held it in 2 quarters. The position peaked at $364K in Q3 2022. 232 funds tracked by Wall St. Rank hold EVH as of Q4 2022.

  • Thompson Davis & Co reported no remaining Evolent Health position as of Q4 2022 after selling out during the quarter.
  • Thompson Davis & Co sold 10,125 Evolent Health shares in Q4 2022, an estimated $364K.
  • Thompson Davis & Co first reported a position in Evolent Health in Q1 2017 and held it in 2 quarters.
  • Thompson Davis & Co's Evolent Health position peaked at $364K in Q3 2022.
  • 232 funds tracked by Wall St. Rank held Evolent Health as of Q4 2022.

Based on Thompson Davis & Co's 13F filing for Q4 2022, filed 6 Feb 2023.